Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trachoma.

David C W Mabey1, Anthony W Solomon, Allen Foster

  • 1Clinical Research Unit, London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK. david.mabey@lshtm.ac.uk <david.mabey@lshtm.ac.uk>

Lancet (London, England)
|July 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A snapshot of selected neglected tropical disease research using the World Health Organization International Clinical Trials Registry Platform database, 1999-2023.

PLoS neglected tropical diseases·2026
Same author

Double-dose azithromycin mass drug administration, facial cleanliness, and fly control measures for trachoma control in Oromia, Ethiopia (Stronger SAFE): a cluster-randomised controlled trial.

The Lancet. Infectious diseases·2026
Same author

Implementing effective cataract surgical coverage: a comparative qualitative study in Kenya and Nepal.

BMJ global health·2026
Same author

Prevalence of death in people with vision impairment from cataracts before treatment: a case study from Kenya.

The lancet. Healthy longevity·2026
Same author

Unified and Consistent Structure Growth Measurements from Joint ACT, SPT, and Planck CMB Lensing.

Physical review letters·2026
Same author

A Randomised Trial of Three Face-Washing Methods for the Removal of Chlamydia trachomatis From the Faces of Children With Severe Active Trachoma.

Tropical medicine & international health : TM & IH·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Same journal

Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

Lancet (London, England)·2026
Same journal

LGBTQ+ Russians increasingly avoiding doctors.

Lancet (London, England)·2026
See all related articles

Trachoma, an infectious cause of blindness, is controlled by the SAFE strategy. A single oral dose of azithromycin is as effective as long-term topical tetracycline for treating Chlamydia trachomatis.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Public Health

Background:

  • Trachoma is the leading infectious cause of preventable blindness globally.
  • Caused by Chlamydia trachomatis, its transmission is linked to poor sanitation and hygiene.
  • Repeated infections lead to eyelid scarring, lash inversion, corneal abrasion, and vision loss.

Purpose of the Study:

  • To summarize the epidemiology and control strategies for trachoma.
  • To highlight the efficacy of the SAFE strategy in trachoma prevention and treatment.
  • To emphasize the significance of azithromycin in simplifying treatment regimens.

Main Methods:

  • Review of trachoma's pathogenesis and transmission dynamics.
  • Description of the components of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement).

Related Experiment Videos

  • Evaluation of antibiotic treatment efficacy, comparing oral azithromycin with topical tetracycline.

    • Main Results:

    • The SAFE strategy provides a comprehensive approach to trachoma control.
    • A single oral dose of azithromycin is as effective as a 6-week course of topical tetracycline.
    • This advance simplifies treatment, improving adherence and public health impact.

    Conclusions:

    • Trachoma elimination is achievable through the integrated SAFE strategy.
    • Azithromycin's efficacy and ease of administration are crucial for large-scale control programs.
    • Continued efforts in surgery, antibiotics, hygiene, and environmental improvement are essential to meet global elimination goals.